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Abstract
Leukodystrophies (LD) are rare inherited disorders that primarily affect the white matter (WM) of the central nervous system.
The large heterogeneity of LD results from the diversity of the genetically determined defects that interfere with glial cells
functions. Astrocytes have been identified as the primary target of LD with cystic myelin breakdown including those related
to mutations in the ubiquitous translation initiation factor eIF2B. EIF2B is involved in global protein synthesis and its
regulation under normal and stress conditions. Little is known about how eIF2B mutations have a major effect on WM. We
performed a transcriptomic analysis using fibroblasts of 10 eIF2B-mutated patients with a severe phenotype and 10 age
matched patients with other types of LD in comparison to control fibroblasts. ANOVA was used to identify genes that were
statistically significantly differentially expressed at basal state and after ER-stress. The pattern of differentially expressed
genes between basal state and ER-stress did not differ significantly among each of the three conditions. However, 70 genes
were specifically differentially expressed in eIF2B-mutated fibroblasts whatever the stress conditions tested compared to
controls, 96% being under-expressed. Most of these genes were involved in mRNA regulation and mitochondrial
metabolism. The 13 most representative genes, including genes belonging to the Heterogeneous Nuclear Ribonucleo-
protein (HNRNP) family, described as regulators of splicing events and stability of mRNA, were dysregulated during the
development of eIF2B-mutated brains. HNRNPH1, F and C mRNA were over-expressed in foetus but under-expressed in
children and adult brains. The abnormal regulation of HNRNP expression in the brain of eIF2B-mutated patients was
concomitant with splicing dysregulation of the main genes involved in glial maturation such as PLP1 for oligodendrocytes
and GFAP in astrocytes. These findings demonstrate a developmental deregulation of splicing events in glial cells that is
related to abnormal production of HNRNP, in eIF2B-mutated brains.
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Introduction
Leukodystrophies (LD) represent a heterogeneous group of rare
genetic disorders primarily affecting the white matter (WM) of the
central nervous system (CNS). The WM is a complex structure
composed of a vast number of axons unsheathed by a compact and
lipid-rich membrane, the myelin. Beside myelinated axons, WM
contains a variety of cells known as glial cells (astrocytes,
oligodendrocytes and microglial cells) that play structural,
metabolic and trophic roles for myelin and axons [1]. The large
heterogeneity of LD results from the diversity of the genetically
determined defects that interfere with glial cells functions. A
common point in the LD physiopathology is the demyelination
and/or development failure (hypomyelination) of CNS myelin
from various origins [2]. The hypomyelinating group of LD
includes diseases due to defects in myelin production or quality.
The main causative gene of hypomyelinating LD controls by
means of oligodendrocytes the production of the major brain
myelin proteins, the proteolipid proteins (PLP). The demyelinating
group of LD includes mainly defects in i) peroxisomal or lysosomal
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2enzymatic activities important for myelin biogenesis and mainte-
nance, or ii) astrocytes functions responsible for progressive cystic
myelin breakdown. This last group of vacuolating LD involves
mainly genes expressed in astrocytes such as GFAP (Glial Fibrillary
Acidic Protein) and MLC1 (Megalencephalic Leukoencephalopathy with
subcortical Cysts 1) or genes ubiquitously expressed as the five
EIF2B1-5 genes encoding the general translation eukaryotic
initiation factor 2B (eIF2B).
EIF2B mutations have been initially described in childhood
ataxia with central hypomyelination (CACH)/Vanishing white
matter (VWM) syndrome characterised in infants by a progressive
neurological deterioration exacerbated by episodes of febrile
infections or head trauma and a cerebrospinal fluid-like signal
intensity of the WM on brain magnetic resonance imaging [3,4].
EIF2B mutations have been subsequently observed in a wide
clinical spectrum from congenital rapidly lethal forms to slowly
progressive adult forms associated in some cases with ovarian
failure [5–9]. A correlation between age at disease onset and
disease severity has been established: disease onset ,2, from 2 to 5
or .5 years are associated respectively to severe, classical or mild
phenotypes [10].
eIF2B is involved in the translation initiation regulation
particularly under cellular stress by activating the eIF2 complex
thanks to its nucleotide guanine exchange factor (GEF) activity. A
correlation between the eIF2B GEF activity and the disease
severity has been established particularly in the most severely
affected infantile group [11,12]. A hyper-activation of the
endoplasmic reticulum (ER)-stress response mediated by the
activating transcription factor 4 (ATF4) has been observed in rat
oligodendroglial-derived cells expressing mutated human EIF2B5
gene [13] as well as in primary fibroblasts [14] and cerebral WM
from eIF2B-mutated patients [15,16] but not in lymphocytes and
lymphoblasts from eIF2B-mutated patients [17] suggesting cell-
specific response to this genetic defect.
The neuropathological features of eIF2B related disorders show
an increased oligodendrocytic density [18,19] and a reduced
number of dystrophic astrocytes due to their abnormal maturation
[20], suggesting an abnormal glial cell maturation in the WM
susceptibility to eIF2B mutations. Moreover, mild transitory
abnormal myelination has been reported in mice homozygous
for a mutant Eif2b5 allele (Eif2b5
R132H/R132H mice) with an early
defect of glial cells proliferation and maturation [21].
In order to identify genes and metabolic pathways specifically
involved in eIF2B-related disorders, we performed a differential
transcriptomic analysis using patients’ fibroblasts with or without
ER stress conditions. Fibroblasts of eIF2B-mutated patients with a
severe, early infantile form, were compared to age matched
fibroblasts of controls as well as patients with other types of LD
(OL-patients). We described here for the first time genes involved
in the mRNA splicing machinery as actors in the abnormal
maturation of glial cells observed in the eIF2B-mutated patient
brains.
Results
70 Genes Specifically and Differentially Expressed in
eIF2B-mutated Fibroblasts
In order to identify genes specifically involved in eIF2B-related
disorders, we performed a transcriptomic analysis comparing
fibroblasts of 10 eIF2B-mutated patients with 10 of OL-patients
and with to 10 age matched control fibroblasts (Table 1). ANOVA
was used to identify genes that were statistically significantly
differentially expressed between eIF2B-mutated and OL-cells at
basal state and after ER-stress by thapsigargin treatment.
Thapsigargin is a blocker of the ER calcium pump. The pattern
of differentially expressed genes between basal state and
thapsigargin treatment in the eIF2B-mutated, OL and control
cells did not differ significantly. These results suggest that ER-
stress does not enhance the effect of eIF2B mutations and is
probably not directly involved in the specific expression profile of
eIF2B-related disorders in cultured skin fibroblasts.
Two hundred fifty three genes were differentially expressed
(FDR#0.12%) between the eIF2B-mutated fibroblasts and control
fibroblasts whatever the stress conditions tested. Among these 253
genes, 70 genes were specifically differentially expressed in eIF2B-
mutated cells when compared with OL fibroblasts, and with
significant expression rate, considered as significant mean ratios
eIF2B-mutated/mean control values #0.9 or $1.05 (Table S1).
Sixty-seven of the 70 genes (96%) were under-expressed whereas
only three genes were weakly over-expressed (range over-
expression rate 1.06 to 1.07). These under-expressed genes are
involved in (a) transcription or mRNA stabilization and splicing
(25%), (b) mitochondria metabolism (15%), (c) development (12%),
(d) cell cycle (10%), (e) DNA compaction or repair (8%), (f)
cytoskeleton (5%), (g) protein synthesis (4%), and (h) other
metabolic pathways (21%) (Table S1).
RNA Processing Deregulation in eIF2B-mutated
Fibroblasts
The 70 genes were analysed using the BBSPE function of the
Genomatix software, in order to select biological processes mostly
and specifically involved in eIF2B-related disorders. We found that
the highest number of genes were all linked to RNA process:
mRNA metabolic process (z-score: 10.08), mRNA processing (z-
scores: 9.74 and 8.91) and mRNA splicing (z-scores: 9.54 to 8.03).
This group statistically diverges form the other biological processes
with a z-score difference of 1. As an example, 8.6% from these 70
deregulated genes are HNRNP genes.
Expression Deregulation of Several Genes in eIF2B-
mutated Fibroblasts Confirmed by mRNA Quantification
We selected 10 under-expressed genes for microarray data
validation according to their putative link with the physiopathol-
ogy of eIF2B-related disorders (Table 2). Among the group of 70
differentially expressed genes described above, we first chose three
genes involved in transcription or mRNA stabilization and
splicing: HNRNPH1, HNRNPL and HNRNPC due to the tight
regulation of the alternative splicing of the major myelin protein
mRNA during myelin formation and maintenance [22–25]. We
added also the HNRNPF gene to the analysis, yet not selected using
our statistical approach (FDR.0.12 for this gene), due to the
particular role of hnRNPH1 and hnRNPF controlling the PLP1/
DM20 mRNA alternative splicing described recently in oligoden-
drocytes [26]. We also selected among our group of 70
differentially expressed genes five genes related to mitochondria
structure and metabolism, MRPS26 (Mitochondrial Ribosomal Protein
S26), MRPL28 (Mitochondrial Ribosomal Protein L28), HCCS (Holocy-
tochrome c Synthase), VDAC3 (Voltage-Dependent Anion-selective Channel
protein 3) and KIF5B (Kinesin Family member 5B) due to the potential
key role of mitochondria in WM homeostasis as suggested by the
involvement of mitochondrial defects in various neurodegenerative
disorders [27] including KIF5A in one inherited progressive
primary motor axonopathy (SPG10) [28]. One gene related to
follicle development and spermatogenesis, DIAPH3 (Diaphanous
Homolog 3), the human homolog of the drosophila Diaphanous gene
[29], was also selected due to the frequent ovarian dysfunction
observed in eIF2B-related disorders.
Splice Defects in EIF2B-Related Disorder
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38264T
a
b
l
e
1
.
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
o
f
s
u
b
j
e
c
t
s
a
n
d
f
i
b
r
o
b
l
a
s
t
s
u
s
e
d
i
n
o
u
r
d
i
f
f
e
r
e
n
t
i
a
l
t
r
a
n
s
c
r
i
p
t
o
m
i
c
a
n
a
l
y
s
i
s
.
A
f
f
e
c
t
e
d
p
a
t
i
e
n
t
n
u
m
b
e
r
T
y
p
e
o
f
L
D
A
g
e
a
t
d
i
s
e
a
s
e
o
n
s
e
t
D
i
s
e
a
s
e
d
u
r
a
t
i
o
n
*
M
u
t
a
t
e
d
g
e
n
e
M
o
l
e
c
u
l
a
r
o
r
b
i
o
c
h
e
m
i
c
a
l
d
e
f
e
c
t
G
e
n
d
e
r
A
g
e
s
k
i
n
b
i
o
p
s
y
F
b
p
a
s
s
a
g
e
s
C
o
n
t
r
o
l
s
u
b
j
e
c
t
n
u
m
b
e
r
G
e
n
d
e
r
A
g
e
a
t
s
k
i
n
b
i
o
p
s
y
F
b
p
a
s
s
a
g
e
s
2
9
1
-
1
E
R
D
2
.
3
y
2
.
7
y
E
I
F
2
B
5
c
.
3
3
8
G
.
A
/
c
.
1
1
6
0
A
.
G
F
9
y
5
1
5
3
0
-
1
F
9
y
7
3
7
5
-
1
E
R
D
2
.
6
y
3
y
E
I
F
2
B
5
c
.
3
3
8
G
.
A
/
c
.
1
9
4
8
G
.
A
F
2
,
7
y
4
1
5
4
5
-
1
F
1
6
m
5
3
9
3
-
1
E
R
D
0
.
9
y
0
.
7
y
E
I
F
2
B
5
c
.
9
2
5
G
.
C
/
c
.
9
2
5
G
.
C
F
1
3
m
3
1
5
4
0
-
1
F
1
5
m
8
3
9
3
-
2
E
R
D
0
.
8
y
0
.
8
y
E
I
F
2
B
5
c
.
9
2
5
G
.
C
/
c
.
9
2
5
G
.
C
F
1
1
m
4
1
5
4
1
-
1
F
9
m
6
4
3
1
-
1
E
R
D
1
,
5
y
3
.
5
y
E
I
F
2
B
5
c
.
3
3
8
G
.
A
/
c
.
1
8
8
4
G
.
A
F
3
,
6
y
4
1
1
7
8
-
1
F
5
y
1
0
4
3
2
-
2
E
R
D
1
.
5
y
2
.
5
y
E
I
F
2
B
5
c
.
2
7
1
A
.
G
/
c
.
1
0
1
5
C
.
T
M
3
,
5
y
7
1
5
9
6
-
1
M
3
y
8
5
9
0
-
2
E
R
D
1
y
3
.
5
y
E
I
F
2
B
5
c
.
1
0
2
8
A
.
G
/
c
.
1
1
5
3
A
.
G
F
3
y
3
1
1
7
8
-
2
F
3
y
8
8
9
4
-
1
E
R
D
0
.
6
y
1
0
d
E
I
F
2
B
5
c
.
5
8
4
G
.
A
/
c
.
5
8
4
G
.
A
M
7
m
3
1
5
3
9
-
1
M
8
m
8
8
9
4
-
2
E
R
D
0
.
4
y
1
0
d
E
I
F
2
B
5
c
.
5
8
4
G
.
A
/
c
.
5
8
4
G
.
A
F
5
m
3
1
5
3
8
-
1
F
6
m
1
1
1
0
3
6
-
1
E
R
D
0
.
8
y
6
m
E
I
F
2
B
5
c
.
9
6
7
C
.
T
/
c
.
1
2
8
0
C
.
T
M
1
2
m
3
1
5
3
7
-
1
M
1
0
m
9
3
5
1
-
1
A
D
1
y
N
A
G
F
A
P
c
.
7
2
9
C
.
T
F
7
y
4
1
1
7
8
-
3
F
8
y
1
0
6
7
2
-
1
A
D
6
m
N
A
G
F
A
P
c
.
2
4
3
A
.
T
F
6
,
6
y
5
1
5
9
4
-
1
F
7
y
6
1
3
0
3
-
1
A
D
N
A
N
A
G
F
A
P
c
.
2
4
9
C
.
T
F
3
,
5
y
4
1
1
7
8
-
2
F
3
y
8
2
5
6
-
1
M
L
C
3
y
N
A
M
L
C
1
c
.
2
4
9
G
.
T
/
c
.
I
V
S
5
+
6
T
.
G
M
1
5
y
5
1
1
7
8
-
4
M
1
7
y
1
0
7
7
3
-
1
M
L
C
3
,
5
y
N
A
M
L
C
1
c
.
1
3
5
i
n
s
C
/
c
.
1
3
5
i
n
s
C
F
4
,
7
y
3
1
1
7
8
-
1
F
5
y
1
0
1
1
4
3
-
1
S
L
S
2
m
N
A
A
L
D
H
3
A
2
d
e
c
r
e
a
s
e
d
F
A
L
D
H
a
c
t
i
v
i
t
y
F
4
y
6
1
6
0
0
-
1
F
4
y
6
1
1
7
9
-
1
S
L
S
A
t
b
i
r
t
h
N
A
A
L
D
H
3
A
2
d
e
c
r
e
a
s
e
d
F
A
L
D
H
a
c
t
i
v
i
t
y
M
3
y
9
1
5
9
6
-
1
M
3
y
1
0
7
7
1
-
1
K
B
3
.
5
m
N
A
G
A
L
C
d
e
c
r
e
a
s
e
d
b
-
g
a
l
a
c
t
i
v
i
t
y
F
8
m
3
1
5
3
9
-
1
F
8
m
9
1
6
7
-
1
P
M
D
1
m
N
A
P
L
P
1
P
L
P
1
d
u
p
l
i
c
a
t
i
o
n
M
4
y
7
1
1
7
8
-
5
M
5
y
7
7
6
7
-
1
P
M
D
A
t
b
i
r
t
h
N
A
P
L
P
1
c
.
4
5
4
-
1
G
.
A
/
c
.
4
5
4
-
1
G
.
A
M
2
y
4
1
5
9
8
-
1
M
2
y
5
L
D
:
l
e
u
k
o
d
y
s
t
r
o
p
h
y
,
E
R
D
:
e
I
F
2
B
-
r
e
l
a
t
e
d
d
i
s
o
r
d
e
r
,
A
D
:
A
l
e
x
a
n
d
e
r
d
i
s
e
a
s
e
,
M
L
C
:
C
y
s
t
i
c
M
e
g
a
l
e
n
c
e
p
h
a
l
o
p
a
t
h
y
,
S
L
S
:
S
j
o
¨
g
r
e
n
-
L
a
r
s
s
o
n
s
y
n
d
r
o
m
e
,
K
B
:
K
r
a
b
b
e
d
i
s
e
a
s
e
,
P
M
D
:
P
e
l
i
z
a
e
u
s
-
M
e
r
z
b
a
c
h
e
r
d
i
s
e
a
s
e
,
y
:
y
e
a
r
,
m
:
m
o
n
t
h
s
,
d
:
d
a
y
,
b
-
g
a
l
:
b
e
t
a
-
g
a
l
a
c
t
o
s
i
d
a
s
e
,
F
:
f
e
m
a
l
e
,
M
:
m
a
l
e
,
F
b
:
f
i
b
r
o
b
l
a
s
t
s
,
N
A
:
n
o
t
a
v
a
i
l
a
b
l
e
.
*
d
i
s
e
a
s
e
d
u
r
a
t
i
o
n
i
n
y
e
a
r
,
c
o
r
r
e
s
p
o
n
d
i
n
g
t
o
t
h
e
t
i
m
e
b
e
t
w
e
e
n
a
g
e
a
t
d
i
s
e
a
s
e
o
n
s
e
t
a
n
d
d
e
a
t
h
o
r
c
o
n
f
i
n
e
m
e
n
t
t
o
b
e
d
w
i
t
h
l
o
s
s
o
f
n
e
u
r
o
d
e
v
e
l
o
p
m
e
n
t
a
b
i
l
i
t
i
e
s
a
n
d
n
e
e
d
o
f
c
o
n
s
t
a
n
t
a
s
s
i
s
t
a
n
c
e
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
3
8
2
6
4
.
t
0
0
1
Splice Defects in EIF2B-Related Disorder
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e38264We quantified the mRNA level of the 10 selected genes by
QRT-PCR on the same RNA samples used for microarray
analysis: 10 eIF2B-mutated patient/control fibroblasts couples and
10 OL-patient/control fibroblasts couples in stressed and non
stressed conditions. For each gene, the determination correlation
coefficient (R
2) between microarray normalized log ratios patient/
control and QRT-PCR delta Ct (patient-control) have been
calculated (Table 3). Among the ten eIF2B-mutated patient/
control couples, lack of correlation between QRT-PCR and
microarray data for 8 of the selected genes (except HNRNPH1 and
MRPS26 genes) was found for two couples (393-2/1541-1 and
431-1/1178-1, data not shown); therefore these couples were
subsequently excluded for the global correlation analysis. For six
genes, the correlation coefficients were significantly higher (range
of p-value 0 to 0.030) in the 8/10 eIF2B-mutated patient/control
fibroblasts couples than in the 10 OL-patient/control fibroblasts
couples (Table 3). The difference between eIF2B-mutated/control
and OL-patient/control couples was high but not significant for
the HCCS and HNRNPC genes (respective p-value =0.152 and
0.144). No significant difference was observed for the KIF5B and
MRPS26 genes (respective p-value =0.876 and 0.736). These
results confirm the specificity of the quantitative differential
expression of 6/10 selected genes in the eIF2B-mutated patient’s
fibroblasts.
Expression of Several Genes Deregulated During the
Development of eIF2B-mutated Brains
We assayed the mRNA level of the 10 selected genes by QRT-
PCR in the brain autopsy samples of two eIF2B-mutated foetuses,
seven children and two adults age matched with controls (Tables 4
and 5). We also included in this study three additional HNRNP
genes (HNRNPU, HNRNPD and HNRNPR), that were present in
the 70 initial genes, due to the high representation of the HNRNP
genes (8.6%) among the deregulated genes. An over-expression
was globally observed in eIF2B-mutated foetal brains compared to
controls except for HCCS and VDAC3 whose mRNA expression
did not vary (Figure 1A). Nevertheless, a lower mRNA expression
was globally observed in the eIF2B-mutated children and adult
brain samples compared to the age-matched control brains,
excluding DIAPH3 that was under-expressed in the eIF2B-mutated
children brains but over-expressed in the adult brains (Figure 1A).
These results demonstrated that genes specifically under-expressed
in eIF2B-mutated fibroblasts of children, in comparison to controls
and to OL-patients, are also globally under-expressed in eIF2B-
mutated children brains. Interestingly, these genes are over-
expressed in eIF2B-mutated foetal brains suggesting a develop-
mental deregulation.
We then focused our analysis on the protein levels of HNRNP,
and particularly on HNRNPL and U by testing one eIF2B-
mutated foetus brain (only one brain was available for protein
extractions), six eIF2B-mutated children brains and two eIF2B-
mutated adult brains in comparison to associated controls. As
shown in Figure 1B, the relative amounts of these proteins seem to
increase in the nuclear fraction of the eIF2B-mutated foetal brain,
consistently with the previous results on transcripts found in two
affected foetus brains. Moreover, we can observe an over-
expression of HNRNPL in the nuclear fraction of the eIF2B-
mutated foetus brain compared to cytoplasmic fraction, which is
totally inverted in the control brains. Nevertheless, the protein
analysis of only one foetal brain did not allow us to demonstrate a
statistically significant deregulation (Figure 1B). Protein analysis of
the children (Figure 1C) and adult brains (Figure 1D) using
western blotting showed variability in HNRNL and U expressions
that did not allow us to demonstrate a statistically significant
deregulation between control and eIF2B-mutated brains at the
protein level.
Abnormal Splice Regulation of PLP1 and GFAP in Brains
from eIF2B-mutated Patients
We next wanted to know if the deregulation observed in the
expression of genes implicated in the mRNA stabilization and
splicing (e.g. HNRNP) has functional consequences. For this
purpose, we first studied the PLP/DM20 mRNA alternative
splicing, known to be regulated during oligodendrocytes matura-
tion by hnRNPH1 and hnRNPF: reduction in HNRNPH1 and F
expression in differentiated mouse oligodendrocytes correlates
Table 2. List of the genes selected for QRT-PCR analysis.
Gene name Description Taqman Gene Expression Assay reference
HNRNPF Heterogeneous nuclear ribonucleoprotein F Hs01014497_ml
DIAPH3 Diaphanous homolog 3 Hs01107326_ml
VDAC3 Voltage-dependent anion-selective channel protein 3 Hs01091534_ml
HNRPL Heterogeneous nuclear ribonucleoprotein L Hs00704850_gl
MRPL28 Mitochondrial ribosomal protein 28 L Hs00371771_ml
HNRPH1 Heterogeneous nuclear ribonucleoprotein H Hs01033845_gl
HCCS Holocytochrome C synthase Hs00403938_ml
HNRPC Heterogeneous nuclear ribonucleoprotein C Hs01028912_ml
MRPS26 Mitochondrial ribosomal protein 26 S Hs00258287_ml
KIF5B Kinesin family member 5 B Hs00189659_ml
HNRNPU Heterogeneous nuclear ribonucleoprotein U Hs00244919_m1
HNRNPD Heterogeneous nuclear ribonucleoprotein D Hs00606052_m1
HNRNPR Heterogeneous nuclear ribonucleoprotein R Hs00195167_m1
PLP Proteolipid protein 1 Mm00456892_m1
PLP/DM20 Proteolipid protein 1 Mm00456894_m1
Gene names, descriptions and Taqman Gene Expression Assay reference used for QRT-PCR quantitation are mentioned.
doi:10.1371/journal.pone.0038264.t002
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38264temporally with increased Plp/Dm20 ratio [26]. DM20 results
from an alternative splicing of the PLP1 gene resulting in exclusion
of part of the exon 3 (Figure 2A). To gain insight into the splice
PLP/DM20 in the eIF2B-mutated patients’ brains, we quantified
by QRT-PCR the isoform PLP alone and PLP+DM20 in the brain
autopsy samples previously used for HNRNP analysis (Table 3). As
expected, PLP and PLP+DM20 transcripts were undetectable or
very low in the control foetal brains, and increasing in the
children/adult brains consecutively to the myelination (Figure 2B,
C). PLP and PLP+DM20 transcripts remained under-expressed in
the eIF2B-mutated brains compared to controls, in correlation
with the hypomyelination observed in eIF2B-related disorders
(Figure 2B, C). However, the PLP+DM20/PLP ratio was
significantly increased in eIF2B-mutated foetal brains compared
to controls (Figure 2D). As a result, the extrapolation of the
calculated DM20 expression alone (PLP+DM20)-PLP, and the
representation of DM20/PLP+DM20 showed an increased ratio
in eIF2B-mutated foetal brains compared to controls (Figure 2E).
These results demonstrated an abnormal upregulation of the
DM20 isoform during foetal life in the affected brains.
The protein levels of PLP and DM20 and the quantification of
the ratio PLP+DM20/PLP showed no differences between the
control and patient brains at the children/adult stage, correlating
with the QRT-PCR results (Figure 2F). PLP protein was
undetectable in the foetal brains. These results showed a defect
in the regulation of the PLP/DM20 mRNA splice or stability at an
early stage of brain development.
Similarly, we quantified the astrocytic differentially expressed
isoforms of GFAP, GFAPalpha and GFAPdelta (Figure 3A) in the
same brain autopsy samples (Table 3). Pan-GFAP mRNA and the
two isoforms GFAPalpha and GFAPdelta were amplified by QRT-
PCR. The normal expression of the Pan-GFAP mRNA and its
isoform alpha and delta is low at the foetal stage, reaches a peak
during childhood and decreases by adult age (Figure 3B, C, D).
Pan-GFAP and GFAPalpha mRNA are not differentially expressed
between the control and eIF2B-mutated samples at the 3 stages of
development (Figure 3B, C). As a consequence, we observed an
equivalent ratio pan-GFAP/GFAPalpha mRNA in the control and
eIF2B-mutated patient brains (Figure 3E). However, GFAPdelta
mRNA was significantly over-expressed in the eIF2B-mutated
patient brains at every development stages (Figure 3D). The ratios
pan-GFAP/GFAPdelta and GFAPalpha/GFAPdelta increased in the
eIF2B-mutated children/adult brains compared to controls but
not in the eIF2B-mutated foetus brains (Figure 3F, G). A specific
upregulation of the GFAPdelta mRNA isoform was 4.5 and 7 times
higher respectively in eIF2B-mutated children and adult brains.
Western blotting analysis confirmed that GFAPdelta was easier to
detect in the eIF2B-mutated post-natal brains than in controls with
a statistically significant difference in children samples (Figure 3H,
antibody GFAPalpha not available). Similarly to PLP, GFAP
proteins were undetectable in the foetal brains. These results
demonstrate an abnormal splicing or unstable regulation of GFAP
in the eIF2B-mutated patients brains that is more pronounced at
the post-natal stage than in foetal stage.
Table 4. Characteristics of brain samples used for microarray data validation on QRT-PCR (qPCR) and/or western blot (WB) analysis.
Patient number Age at autopsy Gender Mutated gene cDNA mutation Usage
1327 Fœtus 15w F WT WT qPCR, WB
1437 Fœtus 15w M WT WT qPCR, WB
412 Fœtus 19w M WT WT qPCR, WB
46 Fœtus 19w F WT WT qPCR, WB
917 Fœtus 19w M WT WT qPCR
311 Fœtus 24w F WT WT qPCR, WB
393 Fœtus 14w M EIF2B5 p.Val309Leu/p.Val309Leu qPCR
1767 Fœtus 16w F EIF2B5 p.Ala239Pro/p.Ala239Pro qPCR,WB
814 Child 16m M WT WT qPCR, WB
1500 Child 7y M WT WT qPCR, WB
1024 Child 14y M WT WT qPCR, WB
393-2 Child 13m F EIF2B5 p.Val309Leu/p.Val309Leu qPCR, WB
5103 Child 16m M EIF2B NA qPCR, WB
357-1 Child 4y M EIF2B5 p.Arg136Cys/p.Arg339Trp WB
359-1 Child 10y M EIF2B4 p.Pro243Leu/p.Pro243Leu qPCR, WB
NA Child NA EIF2B NA qPCR
1203 Child 7y M EIF2B5 p.Gly386Val/p.Arg113His qPCR, WB
4993 Child 12y M EIF2B NA qPCR, WB
1465 Adult 17y M WT WT qPCR, WB
M3702M Adult 19y M WT WT qPCR, WB
2804 Adult 26y M WT WT qPCR, WB
5017 Adult 24y M EIF2B NA qPCR, WB
5106 Adult 39y F EIF2B5 p.Pro454Ser/p.Arg113His qPCR, WB
y: years, m: months, w: weeks, NA: not available, M: male, F: female, WT: wild type.
doi:10.1371/journal.pone.0038264.t004
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Differential Transcriptomic Analysis in Rare Neurological
Disorders needs Comparison by Variance Analysis of
Related Groups of Disease
In rare inherited neurological disorders, DNA microarray
experiments are directed to detect differential gene expression in
order to identify genes or metabolic pathways important for
diagnostic, prognostic or therapeutic approaches. The novelty of
our study has been to compare transcriptomic profiles of
fibroblasts from eIF2B-mutated patients with fibroblasts of OL-
patients in addition to fibroblasts from control subjects. Moreover,
we consider that comparing the fold change results is a misleading
information offered by microarray experiments [30,31]. We used
analysis of variance with the GeneANOVA software [32] to
compare the data taking into account different factors such as
Figure 1. Expression rates of the 13 selected mRNA and two hnRNP proteins in eIF2B-mutated fœtal and patients brains. A. RNA was
isolated from brains and analyzed by quantitative RT-PCR for expression of the 13 selected genes. Expression rates were calculated using the formula
Mean (2
‘-(delta (patient)- delta (control))) where delta (patient) correspond to (Ct gene x 2 Ct B2M) for one patient and delta (control) to (Ct gene x 2
Ct B2M) for the corresponding control. Errors bars represent standard error (s.e.m.) (*P,0.05, **P,0.01, ***P,0.001). B–D. To assess the expression of
hnRNPL and hnRNPU proteins in the brain autopsy samples, a nuclear and cytoplasmic differential extraction were performed followed by western
blot analysis using antibodies specific for hnRNPL and U. GAPDH served as loading control. H3K27 served as a nuclear control. Are represented in B
the fetuses samples, in C the children samples and in D the adults samples. C: control, M: eIF2B-mutated.
doi:10.1371/journal.pone.0038264.g001
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38264disease status, couple number and ER-stress treatment between
the different groups of fibroblasts: eIF2B-mutated, OL and
controls. This type of statistical analysis allowed us to maximize
the use of available data (relative transcription level of the
corresponding gene and systematic bias due to the protocol such as
labelling efficacy).
ER-stress Activation is not Specific to eIF2B-related
Disorders
A hyper-activation of ER-stress response has been reported in
fibroblasts from eIF2B-mutated patients [14], or rat oligoden-
droglial-derived cells expressing mutated human EIF2B5 gene
[13]. An UPR (unfolded protein response) hyper-activation has
Figure 2. Study of the splice PLP/DM20 in eIF2B-mutated patients brains. A. Transcripts of human PLP1 splice variants. The boxes represent
the exons that are transcribed for the different isoforms. The black and grey arrows represent respectively common primers between PLP and DM20
(forward primer between the exons 5 and 6, reverse primer at the end of the exon 6), and specific primers for PLP (forward primer between the exons
3b and 4, reverse primer in the exon 4). B, C. RNA was isolated from control brains (white bars) vs eIF2B-mutated patient brains (black bars) and
analyzed by quantitative RT-PCR for expression of PLP and PLP+DM20. Expression rates were calculated using the formula Mean (2
‘-(Ct gene x 2 Ct
B2M)) and ratio PLP+DM20/PLP was performed (D). E. Extrapolation of the DM20/PLP+DM20 ratio calculating DM20 alone by the formula (PLP+DM20)-
PLP. Errors bars represent standard error (s.e.m.) (*P,0.05,**P,0.01, ***P,0.001).F. Proteins were extracted from controls and eIF2B-mutated patient
brains and western blot analysis was performed on the cytoplasmic fractions using antibodies specific for PLP and DM20. GAPDH served as loading
control. C: control, M: eIF2B-mutated. The images were quantified using ImageQuant TL software and the box plots below show the relative
expression of PLP+DM20/PLP (corrected for GAPDH levels) in control and patients brains. A.V.: arbitrary value.
doi:10.1371/journal.pone.0038264.g002
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e38264Figure 3. Study of the splice GFAP in eIF2B-mutated patients brains. A. Transcripts of human GFAP splice variants. The boxes represent the
exons that are transcribed for the different isoforms. The termination codon, indicated by a blocked round circle, is located in exon 9 for GFAPalpha,
and in exon 7a for GFAPdelta. The black and grey arrows represent respectively common primers between GFAPalpha and GFAPdelta (forward primer
between the exons 1 and 2, reverse primer between exons 2 and 3), and specific primers for each isoforms (forward primer between the exons 8 and
9, reverse primer in the exon 9 for the GFAPalpha isoform, forward primer in the exon 6, reverse primer between the exons 7 and 7a for the GFAPdelta
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e38264also been described in brains from eIF2B-mutated patients
compared to control individuals [15] and to a single PMD case
[16]. Our transcriptomic analysis showed that ER-stress induced
by thapsigargin did not help to differentiate gene expression profile
of eIF2B-mutated fibroblasts from leucodystrophic fibroblasts of
other causes. We explain this discrepancy as our 10 eIF2B-
mutated patients expressed a homogenous severe phenotype and
were compared for the first time to a group of infantile severe
forms of leukodystrophic patients from various other causes
including patients with other type of vacuolating LD. This suggests
that the ER-stress response observed in eIF2B-mutated cells has no
specificity despite the role of the eIF2B complex in translation
regulation after stresses. Stress, classically reported as an onset
trigger or aggravating factor in eIF2B-related disorders [9,33], also
worsened symptoms in other groups of WM disorders particularly
in other types of vacuolating LD. The functions of the ER in
proper folding of proteins, lipids biosynthesis and storage of
calcium could explain the susceptibility of the WM to ER stress,
particularly during the myelination process that requires rapid
synthesis of large amount of proteins and lipids [34].
Specific Genes Involved in eIF2B-related Disorders are
Under-expressed and Belong Mainly to mRNA Regulation
and Mitochondrial Functions
Our transcriptomic analysis identified 70 genes that were
specifically differentially expressed in eIF2B-related disorders and
belonging to three main biological processes.
The first group gathers 25% of the selected genes which are involved in
transcription or mRNA stabilization and splicing, with a high z-score for
the associated biological processes, suggesting a major disturbance
of mRNA regulation. We identified six genes belonging to the
HNRNP family (HNRNPH1/C/D/L/U/F and R) and two MBNL
genes (MBNL1 and MBNL2: Muscle blind like 1 and 2) which were
involved in mRNA splicing or mRNA stability and transport
suggesting that splicing and stabilization of a large panel of mRNA
can be affected in the eIF2B-related disorders. Alternative splicing,
widely used to generate protein diversity and to control gene
expression, is highly abundant in brain relative to other tissues
[35,36]. It may generate cell-specific combination of protein
isoforms that define the functional properties of the cells and
underline complex processes such as synaptic adhesion and CNS
plasticity [37]. Most of the main specific myelin proteins are
submitted to alternative splicing, such as PLP/DM20 [24,25],
MAG (Myelin-Associated Protein) [22] or MBP (Myelin Basic
Protein) [38] and the production of the different isoforms during
myelination have to be tightly regulated. Indeed, it has been
demonstrated that the hnrnpH1 and F proteins control the
alternative splicing of the Plp/Dm20 mRNA in a mouse
oligodendroglial cell line [26]. The knock-down of these hnRNP
proteins by siRNA modified the Plp/Dm20 mRNA ratio by
increasing the production of the Plp mRNA isoform. Moreover, a
recent study demonstrated that over-expression of HNRNPC2 in a
human neuroblastoma cell line up-regulated the message level of
MBP [39]. The identification of an increase of such a number of
HNRNP genes in foetal brains together with their decrease in
children and adult brains suggests that eIF2B mutations may have
a major effect on myelination timing and myelin maintenance.
These results are in agreement with the recent microarray analysis
performed in Eif2b5-mutated mice brains where authors described
a down-regulation of oligodendrocyte-specific genes at specific
time point during the development [40]. Analysis of the published
microarray results of Eif2b5-mutated mice brains showed a
decrease in Hnrnp genes (e.g. HnrnpH1) at postnatal day 18 and
21 (P18 and P21), corresponding to the peak period of myelin
formation. Here we identified the first link between eIF2B
mutations and a potential myelin defect due to HNRNPH1
mRNA, a key regulator of the major myelin protein PLP/DM20
splicing and the dynamic of the myelin production during the
development. It has also been demonstrated that several HNRNP
shuttle between the nucleus and the cytoplasm, transporting
mature mRNA for translation or regulating mRNA stability [41].
So, the differential localization of HNRNPL and U in the foetal
brains between controls and eIF2B-mutated patients yield to the
hypothesis of a functional consequence on target genes and
processes of these hnRNP.
The Second Group of Selected Genes is Related to
Mitochondria Metabolism and Transport
Interestingly, five genes encoding mitochondrial ribosomal
subunits (MRPS26, MRPL28, MRPL38, MRPL16 and MRPS9)
were under-expressed. This suggests that protein synthesis in
mitochondria is probably also affected by eIF2B mutations. The
identification of some genes involved in the electron transport
pathway (HCCS) or component of the mitochondrial membrane
like VDAC3, mitochondrial respiratory chain (SDHD) and in
mitochondrial transport (KIF5B), suggests that the global metab-
olism of mitochondria is affected in eIF2B-related disorders. In
CNS, mitochondria are notably important for Ca
2+ signalling in
oligodendrocyte precursor cells which seems to be critical during
their migration, proliferation and differentiation [42]. Mitochon-
dria are also essential for neuronal activity [43] and defects in their
functions have been involved in various neurodegenerative
disorders [27], such as SPG10, due to mutations in the neuron-
specific KIF5A gene. Moreover, a study showed that Kif1b is
required for the localization of mbp mRNA to processes of
myelinating oligodendrocytes in zebrafish [44].
Another interesting gene differentially expressed in
eIF2B-mutated patient fibroblasts and brains is the
DIAPH. The human homolog of the Drosophila Diaphanous
gene, involved in cytokinesis [29]. Disruption of the Diaphanous
gene in Drosophila is responsible for spermatids degeneration and
abnormal follicle cells development leading to male and female
infertility. Moreover, another human gene belonging to the
Diaphanous family named DIA is disrupted in a patient with
premature ovarian failure [45]. DIAPH3 has been recently
involved in cell migration, axon guidance and neuritogenesis
[46]. We can therefore hypothesize that it may be also involved in
folliculogenesis, and would explain the ovarian failure sometimes
observed in mild cases of eIF2B-related disorders (ovarioleukody-
strophy) [7].
isoform). B-D. RNA was isolated from control brains (white bars) versus eIF2B-mutated patient brains (black bars) and analyzed by quantitative RT-
PCR for expression of pan-GFAP, GFAPalpha and GFAPdelta. Expression rates were calculated using the formula Mean (2
‘-(Ct gene x 2 Ct B2M)). Ratios
were performed between pan-GFAP and GFAPalpha (E) pan-GFAP and GFAPdelta (F), GFAPalpha and GFAPdelta (G). Errors bars represent standard
error (s.e.m.) (*P,0.05,**P,0.01,***P,0.001). H. Proteins were extracted from controls and eIF2B-mutated patient brains and western blot analysis
was performed on the cytoplasmic fractions using antibodies specific for GFAP delta. GAPDH served as loading control. C: control, M: eIF2B-mutated.
The images were quantified using ImageQuant TL software and the box plots below show the relative expression of PLP+DM20/PLP (corrected for
GAPDH levels) in control and patients brains. A.V.: arbitrary value.
doi:10.1371/journal.pone.0038264.g003
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children/adult eIF2B-mutated brains suggest that eIF2B muta-
tions have different effects depending on the developmental stage.
Nine of the 13 genes tested are significantly over-expressed in
foetal brains but 10 and 8 are under-expressed in children and
adult brains respectively (Figure 1), suggesting that eIF2B
mutations have specific deleterious effects during embryonic life.
Our results coupled to the various congenital abnormalities
observed in the ‘‘congenital’’ forms of eIF2B-pathies (glaucoma,
cataract, dysmorphic features [45]) suggest a larger effect on the
programmed cell differentiation.
Abnormal Splice Regulation of Genes Important for Glial
Cells Maturation is Observed in eIF2B-mutated Brains
In order to further analyse the dysregulation of genes involved
in mRNA stabilization and splicing during the CNS development,
we focussed our attention on two genes with splice isoforms
differently expressed during glial maturation, respectively PLP1 in
oligodendrocytes and GFAP in astrocytes.
We found an up-regulation of the ratio PLP+DM20/PLP
demonstrating an increased expression of the DM20 isoform
specifically in the mutated brains at foetal age (Figure 2). This up-
regulation of DM20 in the eIF2B-mutated foetal brains is
concomitantly associated with an increased expression of
HNRNPH1 and F. Regulation of PLP alternative splicing and
maintenance of the PLP/DM20 ratio are critical for oligodendro-
cytes differentiation and myelin maintenance. In mature myelinat-
ing oligodendrocytes, the PLP 59 splice site is preferentially used,
while in oligodendrocytes progenitor cells and in other cell types,
DM20 is the preferred site [23]. Mutations that impair the PLP/
DM20 ratio cause a spectrum of dysmyelinating disorders in
humans [47,48]. Therefore, alteration of PLP/DM20 mRNA
splicing or isoforms stability related to HNRNP dysregulation could
account for the myelin paucity with substantial increase in the
number of non myelinating oligodendrocytes observed in eIF2B-
related disorders [18,49].
We also found that mutated brains over-express GFAPdelta at all
the developmental stage but not pan-GFAP and GFAPalpha.A sa
consequence, the ratio pan-GFAP/GFAPdelta is down-regulated in
the children/adult mutated brains, whereas it is not affected in the
foetal brains (Figure 2). GFAPdelta results from an alternative
splicing of GFAP gene, which replaces the two final exons of the
predominant isoform GFAPalpha with an alternative terminal exon
[50]. In normal adult grey and WM parenchyma, GFAPdelta
represents only a small fraction of total GFAP [51]. However,
GFAPalpha and delta transcripts are both up-regulated in
Alzheimer’s disease [52]. Moreover, the transient over-expression
of GFAPdelta in a human astrocytoma cell line, destabilizing the
ratio GFAP alpha/delta, results in the formation of cytoplasmic
aggregates that often collapse the endogenous GFAP networks
[51]. Similarly to the present study, an over-expression of the
mRNA and protein isoform GFAPdelta have been recently
reported in the brain WM of an eIF2B-mutated child (4.5 months)
and two adult (12 and 29 years) patients compared to control
brains without differences in the major GFAPalpha isoform and in
the ratio GFAPalpha/pan-GFAP [53]. The abnormal morphology
of mutated astrocytes has been invoked to explain the extensive
WM cavitation and limited gliosis of affected tissues observed in
eIF2B-mutated brains [20]. In the affected WM, astrocytes have
coarse blunt processes instead of the fine arborisations observed in
controls. In the LD related to GFAP mutations (Alexander disease),
the inability to form proper astrocytic GFAP networks coexists
with incomplete maturation of astrocytes and insufficient myelin
formation [54]. Our findings suggest that assembly-compromised
GFAPdelta could alter protein interactions of GFAP filaments,
thereby contributing to the aberrant morphology of affected
astrocytes. This may contribute to the clinical similarity found
between eIF2B and GFAP-related disorders, both being a
cavitated demyelinating LD with stress-induced acute phases [2].
We described here for the first time genes involved in the
mRNA stabilization and splicing machinery as potential actors in
the abnormal maturation of glial cells observed in the eIF2B-
mutated patient brains. However, if the link between the hnRNP
proteins and the abnormal splice of PLP/DM20 mRNA is clear,
the relation between hnRNP and GFAP mRNA splicing remain to
be elucidated.
EIF2B-mutated fibroblasts lack a specific transcriptomic ER-
stress profile but they differentially express genes important for
mRNA regulation (HNRNP), mitochondrial metabolism/trans-
port and gonadogenesis when compared to controls. Moreover,
the abnormal HNRNP mRNA production observed in eIF2B-
mutated brains varies during cerebral developmental and is
concomitant with the splice dysregulation of the main genes
involved in glial maturation. This suggests that the brain
susceptibility of abnormal translation regulation related to eIF2B
mutations involves a developmental expression deregulation of
proteins implicated in mRNA splicing and stabilization machinery
like the hnRNP which play a major role in other neurodegener-
ative disorders.
Materials and Methods
Ethics Statement
Studies have been performed with the ethical agreement of the
‘‘Centre de protection des personnes Sud-Est VI’’, France and a
signed informed consent of the parents. All patients or their legal
guardians gave their written informed consents.
Samples from Fibroblasts of Leukodystrophic Patients
For the differential transcriptomic study, we analysed the
leukodystrophic fibroblasts from ten eIF2B-mutated patients and
from ten patients affected by OL coupled with 20 sex and age-
matched control subjects without neurological signs (Table 1).
In the eIF2B-mutated group, all patients have a severe
phenotype characterised by (i) an early infantile age of onset
(mean 1.260.7 years, range: 5 months to 2.7 years), and (ii) a rapid
progression leading to death or absence of motor and cognitive
capacities in a mean of 1.761.4 years (range: 10 days to 3.5 years)
(Table 1). We selected patients with a severe, early infantile form,
because the impacts of the eIF2B mutations on the phenotype
seem greater than in milder forms in which other environmental
factors are also involved [33].
The 10 patients with OL have also an infantile age of onset
(mean 0.961.3 years, from birth to 3.5 years). They included (i)
five patients with other types of vacuolating LD (three patients
with Alexander disease relative to GFAP mutation and two patients
with megalencephalic leukoencephalopathy with subcortical cysts
related to MLC1 mutations), (ii) two patients with a severe
congenital form of hypomyelinating LD caused by PLP1 mutations
PMD form 0 without motor acquisition), (iii) three patients with a
demyelinating LD related to lipid metabolism enzymatic defect
with a rapid progression in one case of Krabbe disease and a
slower disease evolution in two cases of SLS (Table 1).
Samples from Patients’ Brains
Affected brain tissues used for quantitative real-time PCR gene
analysis (Tables 4 and 5), provided from the brains samples of two
eIF2B-mutated fœtuses (393 and 1767), were obtained after the
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of gestation due to the affected status of the foetuses found by
DNA’CVS analysis and immediately frozen in liquid nitrogen. In
addition, brain samples of affected patients were identically frozen
immediately after the brain autopsy performed between 13
months and 39 years. Control brain samples (foetus and
children/adults) were provided by the Brain and Tissue Bank
for Developmental Disorders at the University of Maryland,
Baltimore, Maryland (USA) and the fetopathologic unit of the
Clermont-Ferrand University Hospital, (Dr AM Beaufre `re),
Clermont-Ferrand (France).
Cell Culture, Thapsigargin Treatment and RNA Isolation
Primary fibroblasts were obtained from skin biopsy. They were
grown on RPMI 1640 L-Glutamine medium (Gibco) supplement-
ed with 1% Penicillin 1000UI/ml, Streptomycin 10mg/ml,
0,001% Amphotericin B 2,5mg/ml and 10% FBS (Foetal Bovine
Serum) at 37uC and 5% CO2. Twenty-four hours after treatment,
fibroblasts at nearly confluence were trypsinized with 0.1%
trypsin-EDTA and cells were equally divided. One half of the
cells were treated with 1mM thapsigargin and the other half with
0.05% ethanol during 4H at 37uC and were harvested with two
PBS washes just after thapsigargin treatment. Thapsigargin raises
cytosolic calcium concentration by blocking the ability of the cell
to pump calcium into the endoplasmic reticulum which causes
these stores to become depleted. Finally, fibroblasts from 6 control
subjects used as reference were grown, harvested, lysed and RNA
extracted identically to the others. Total RNA from fibroblasts and
from all brain samples were extracted using the RNeasy Lipid
Tissue Mini Kit (Qiagen), according to the manufacturer’s
instructions and stored at 280uC.
RNA Preparation for Microarray Experiments
For each sample, RNA quality and concentration were assessed
using a Bioanalyseur 2100 (Agilent Technologies, Waldbronn,
Germany), according to the manufacturer’s instructions. For
microarray hybridizations, 500 ng of total RNA were directly
labelled by reverse transcription using the Low RNA input linear
amplification (Agilent Technologies) and were purified using the
RNeasy mini kit (Qiagen) according to the manufacturer’s
recommendations. This reaction has been performed for RNA
of each fibroblast of eIF2B-mutated patients, OL-patients and age-
and sex-matched control subjects with Cy3 (green) incorporation.
The reference sample (pool of 6 control subject’s fibroblasts) was
labelled with Cy5 (red) incorporation. All the dye incorporation
rates were checked by ND-1000 spectrophotometer (Nanodrop
Technologies). Fragmentation of cDNA was performed by
denaturating the samples at 60uC during 30 min in order to
obtain cDNA fragments of 50 to 200 nucleotides.
cDNA Microarray Hybridizations and Scanning
Two microarray experiments have been performed with and
without ER-stress conditions: i) M1: cDNA samples of 10 eIF2B-
mutated fibroblasts versus matched coupled controls fibroblasts; ii)
M2: cDNA samples of 10 OL fibroblasts versus matched coupled
controls fibroblasts.
750 ng cDNA (M1) or 825 ng cDNA (M2) of mutated and
controls cells, treated with thapsigargin or ethanol and labelled
respectively with Cy3 and Cy5, were mixed into a single pool with
the hybridization buffer. They were cohybridized on the same
microarray slide (Human pangenomic 44K from Agilent Tech-
nologies) in an Agilent hybridization platform (Imaxio, Diagno-
gene division, Saint-Beauzire, France) at 65uC during 17h.
Microarray slides were then scanned with the following param-
eters: i) M1 experiment: Cy3 Photo Multiplier Tube (PMT): 100,
and Cy5 PMT: 100 with a 10 mM resolution; ii) M2 experiment:
parameters for Cy3 and Cy5: Xdr High 100% 2Xdr Low 10%
with a 5 mM resolution, the Xdr corresponding to two scans (one
at PMT 100 and one at PMT 10). These processes were repeated
for each of the 40 hybridized slides. The images were analyzed
with the Feature Extraction 9.1 software (Agilent Technologies)
using the GE2-v4_91 (M1) or GE2-v5_95 (M2) protocols
according to the manufacturer’s instructions.
cDNA Microarray Data Analysis
The statistical analysis was performed for characterized genes.
EST and chromosomal location (LOC) have been excluded.
Correction and normalization. Transformation and nor-
malization of hybridization data were performed to minimize
variations arising from technical differences in RNA quality, probe
labelling, and hybridization conditions between experiments. The
repartition of the gene expression rates is asymmetric with a small
number of high values leading us to perform a logarithmic
transformation and standardisation for each signal intensity (giving
the ‘‘log values’’). Correction was next performed for differences in
the variability across the range of gene expression levels using the
formula : (corrected G log value)i = (G log value)i – (R log value)i
+ (mean R log value)i; where ‘‘G log value’’ represents sample
signal intensity, ‘‘R log value’’ represents the reference signal
intensity, and ‘‘mean R log value’’ represents the mean of all R
values obtained for the gene ‘‘i’’ in reference across the different
conditions.
Identification of Genes Specific of eIF2B-related Disorder
Genes differentially expressed (i) between the eIF2B-mutated
patients and the control subjects for the M1 and (ii) between the
OLs-patients and the control subjects for the M2, were determined
statistically by variance analysis using the GeneANOVA software
[32]. For M1 and M2 analyses, we constructed a statistical model
including 3 factors: disease status (patients or control subjects),
patients’ couple (couple 1 to 10) and treatment (thapsigargin or
ethanol). Then we identified genes specific of eIF2B-related
disorder by comparing the experiments M1 and M2 and the
genes differentially expressed between the eIF2B-mutated patients
and the OLs-patients were determined statistically by variance
analysis using the GeneANOVA software [32]. We constructed a
statistical model including 2 factors: disease status (patients or
Table 5. List of the genes quantified by QRT-PCR analysis.
qPCR Primers Sequence (59-39)
Total GFAP, forward AGAAGCTCCAGGATGAAACC
Total GFAP, reverse TTCATCTGCTTCCTGTCTATAGG
GFAPalpha, forward AGAGGTCATTAAGGAGTCCA
GFAPalpha, reverse CAACTATCCTGCTTCTGCTC
GFAPdelta, forward CCTACAGGAAGCTGCTAGAG
GFAPdelta, reverse GCGTTCCATTTACAATCTGGT
GAPDH, forward CTCTCTGCTCCTCCTGTTCGAC
GAPDH, reverse TGAGCGATGTGGCTCGGCT
HPRT, forward ATGGGAGGCCATCACATTGT
HPRT, reverse ATGTAATCCAGCAGGTCAGCAA
Transcript-specific primers and their sequences for SYBR Green quantitation are
mentioned.
doi:10.1371/journal.pone.0038264.t005
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variance across each group of patients was included in residual.
In Silico Analyses of the Biological Processes Involved in
eIF2B-related Disorders
Biological processes were analysed using the Genomatix
software, available at http://www.genomatix.de. Using the
BBSPE (Bibliosphere) function, we analysed and selected biolog-
ical processes involving a maximum of the 70 selected genes. For
each biological process, a z-score (or z-value) is calculated: it
expresses the divergence of the experimental result from the most
probable result as a number of standard deviations. The larger the
value of z, the less probable the experimental result is due to
chance. When z-score is over 3, one can consider that the result is
significantly not due to chance.
Gene Expression Analysis of Selected Genes by
Quantitative Real-time PCR (QRT-PCR)
Total RNA extracted from fibroblasts and from the brain
samples were used for gene expression analyses by QRT-PCR of
13 selected genes, as well as PLP/DM20 and GFAP isoforms
(Tables 2 and 3). RT for each sample has been performed with
1mg of total RNA using the High Capacity cDNA Reverse
Transcription kit (Applied Biosystems) according to the manufac-
turer’s instructions. Two independent RT were performed for
each sample and quantitative PCR was performed on Taqman
7300 using the Taqman Probe technology (Applied Biosystems)
with specific probes and primers (Taqman Gene Expression Assay)
for each 13 selected genes and PLP/DM20 isoforms, pre-designed
to overlap exon-exon boundaries and then prevent genomic DNA
amplification. Quantitation was carried-out regarding the house-
keeping beta2-microglobulin (B2M) mRNA. For each selected gene,
4 ml of 1/10 cDNA dilution were amplified with 1X Taqman
Gene Expression Master Mix (Applied Biosystems) and 1X of
Taqman Gene Expression Assay (Tables 2 and 3) in a final volume
of 20 ml. The program included an initial step of UDG incubation
at 50uC for 2 min, a step of enzyme activation at 95uC for 10 min
followed by 40 cycles of 95uC for 15 seconds, 60uC for 1 min. The
QRT-PCR were carried out in duplicates for each RT sample and
each selected gene. The cycle of threshold value (Ct) was used to
calculate the relative expression of the gene of interest and
normalized to the transcript for the housekeeping gene B2M.
Expression rate of QRT-PCR were calculated using the formula
Mean (2
‘-(delta(patient)-delta(control))) where delta(patient) corre-
spond to (Ct gene x 2 Ct B2M) for one patient and delta (control)
to (Ct gene x 2 Ct B2M) for the corresponding control.
For the GFAP isoforms quantifications, transcript-specific
primers were designed to overlap exon-exon boundaries to
prevent genomic DNA amplification [53] (Table 5). The PCR
was carried out using a sample volume of 20 ml containing Power
SYBR Green PCR Master Mix (Applied Biosystems), 10 mM
primers and 4 ml of 1/10 cDNA dilution. The relative abundance
of transcript expression was calculated using the cycle of threshold
value and normalized to the endogenous controls GAPDH
(Glyceraldehyde Phosphate Deshydrogenase) and HPRT (Hypoxanthine-
guanine Phosphoribosyl Transferase). The results were expressed as
mean 6 S.E.M. and compared using the Mann-Whitney test.
Protein Extraction and Western Blot Analysis
To assess the expression of hnRNP proteins in the brain autopsy
samples, we performed a nuclear and cytoplasmic differential
extraction, due to the major nuclear localisation of these proteins,
using the NE-PER nuclear and cytoplasmic extraction reagents
(Thermo Scientific) according to the manufacturer’s instructions.
We validated the fractionation procedure using the anti-trimethyl-
histone H3 (Lys27) (H3K27) antibody, that recognizes a histone
mark specific to the nucleus. The cytoplasmic fractions were also
used for PLP and GFAP detection. Protein concentration was then
assessed by the Bradford method. 10 mg of protein lysates were
separated on 10% SDS-polyacrylamide gel electrophoresis and
transferred to polyvinylidene difluoride membranes (Millipore).
Unspecific binding were blocked with 5% bovine serum albumine
(BSA) in Tris-buffered saline (TBS) containing 0.1% Tween 20
overnight at 4uC. Incubations with primary antibodies were
carried out at room temperature using mouse anti-GAPDH
(1:5000, Abcam, ab8245), mouse anti-hnRNPL (1:8000, Sigma
Aldrich, R4903), mouse anti-hnRNPU (1:8000 for cytoplasmic
fraction and 1:12000 for nuclear fraction, Sigma Aldrich, R6278),
rabbit anti-GFAP (1:1500, Chemicon, ab5804), rabbit anti-GFAP
delta (1:500, Abcam, ab28926), rat anti-PLP (1:200, gift from W
Macklin) and rabbit anti-H3K27 (1:200, Millipore, #07-449).
After washing, membranes were incubated with an accordingly
HRP-conjugated secondary antibody: anti-mouse (1:5000, Amer-
sham), anti-rabbit (1:5000, GE Healthcare) or anti-rat (1:5000,
Rockland) at room temperature. Protein expression was detected
by ECL reagent (GE Healthcare).
Bands on the films were quantified with ImageQuant TL
software and compared using the Mann-Whitney test.
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